Understanding Hemophilia B
Hemophilia B is an inherited bleeding disorder caused by a deficiency of clotting Factor IX, leading to prolonged bleeding after injury, surgery, or spontaneously into joints and muscles.
- X-linked inheritance
- Factor IX deficiency
- Lifelong management
- Most Common In
- Males (X-linked recessive)
- Estimated Prevalence
- ~1 in 25,000–30,000 male births
- Deficient Factor
- Factor IX
- Advanced Therapies
- Gene therapy, extended half-life factor
Condition Overview
Hemophilia B is an inherited bleeding disorder caused by mutations in the F9 gene that reduce or eliminate production of clotting Factor IX. It is less common than Hemophilia A but follows a similar pattern of prolonged bleeding after injury and, in severe cases, spontaneous bleeding into joints and muscles.
Types and Classification
Hemophilia B is classified by residual Factor IX activity, which correlates with bleeding severity.
Symptoms and Signs
Symptoms vary with severity and largely mirror those seen in Hemophilia A, centered on abnormal bleeding.
Causes and Risk Factors
Hemophilia B is most often inherited, though a portion of cases arise spontaneously or develop later in life.
Diagnosis and Investigations
Diagnosis combines clinical bleeding history with targeted coagulation laboratory testing.
Severity Classification
Hemophilia B severity is staged by residual Factor IX activity, guiding expected bleeding pattern and treatment intensity.
Standard Treatment
Treatment focuses on replacing or supporting deficient Factor IX to prevent and control bleeding episodes.
Advanced & Emerging Therapies
Gene therapy and extended half-life products are expanding options for long-term management of Hemophilia B.
Gene Therapy
AAV-based Factor IX gene therapy
A single infusion designed to provide sustained endogenous Factor IX production in eligible adults.
Extended Half-Life Factor Concentrates
Modified Factor IX products
Allow less frequent infusions compared to standard Factor IX replacement.
Rebalancing Agents
Anti-TFPI and antithrombin-lowering therapies
Investigational approaches aimed at improving hemostasis independent of Factor IX levels.
Biomarkers & Monitoring
Laboratory markers guide diagnosis, severity classification, and treatment monitoring.
When to Seek a Second Opinion
A second opinion can help confirm diagnosis, optimize prophylaxis, or address treatment-resistant bleeding.
Clinical Trials & Research
Prognosis & Outcomes
With appropriate treatment, most people with Hemophilia B lead active lives, though long-term joint health depends on early and consistent bleed prevention.
Supportive Care
Comprehensive supportive care helps reduce bleeding complications and preserve quality of life.
How CancerFax Helps You Explore Treatment Options
CancerFax helps patients with Hemophilia B access specialist hematology review, evaluate eligibility for gene therapy or extended half-life products, and coordinate care with leading treatment centers.
Get a free case reviewFrequently Asked Questions
Hemophilia B is an inherited bleeding disorder caused by a deficiency of clotting Factor IX, leading to prolonged or excessive bleeding.
Both cause similar bleeding symptoms, but Hemophilia B is due to Factor IX deficiency rather than Factor VIII, and is less common.
There is no widely available cure, but gene therapy in select regions may offer long-term Factor IX production for eligible patients.
Diagnosis involves clotting tests such as aPTT along with a Factor IX activity assay to confirm and grade severity.
Bleeds can occur after injury, surgery, or dental work, and in severe cases, spontaneously into joints or muscles.
An inhibitor is an antibody that neutralizes replacement Factor IX, making standard treatment less effective.
Yes, women can be carriers and pass the gene to their children, and some carriers experience mild bleeding symptoms.
Gene therapy delivers a functional copy of the F9 gene to help the body produce its own Factor IX, reducing or eliminating the need for regular infusions.
Prophylaxis involves regular scheduled infusions to prevent bleeds, while on-demand treatment is given only when a bleed occurs.
Yes. CancerFax assists with medical report review, second opinion coordination, and access to advanced therapies including gene therapy, with support for international treatment coordination where relevant.
Get Expert Guidance on Hemophilia B
Send your medical reports for a specialist review and explore the latest treatment and therapy options available to you.